Literature DB >> 32359910

Paediatric urology practice during COVID-19 pandemic.

Chiara Cini1, Giulia Bortot1, Simone Sforza2, Alberto Mantovani1, Luca Landi1, Ciro Esposito3, Maria Escolino3, Lorenzo Masieri1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32359910      PMCID: PMC7195101          DOI: 10.1016/j.jpurol.2020.04.023

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


× No keyword cloud information.
Dear Editor, Since December 2019, Coronavirus disease 2019 (COVID-19) has occurred unexpectedly and emerged as a health problem worldwide. Up to April,14th 2020, more than 160.000 cases and over 20.000 deaths have been reported in Italy, one of the major countries involved. In contrast, only 1.2% of cases are paediatric with less than 10 deaths recorded worldwide [1]. Signs and symptoms of COVID-19 in adults are well known as one or more among fever, dry cough, dyspnoea, anosmia, ageusia, fatigue and lymphopenia; similarly the manifestations of paediatric patients are superimposable [2]. Indeed, when affected, most children present with mild clinical manifestations or asymptomatic course and usually have a good prognosis with recover within 1–2 weeks after the onset of the disease [3]: children could thus be silent carriers of this highly infectious virus [4]. Considering that in adult centers massive resources are dedicated to COVID-19 and pediatric hospitals have to prepare for possible acceptance of even adults, to avoid unnecessary hospitalization and risks of transmissions, surgical management in these centres must be reorganized. Therefore, we re-evaluated the priority of all children scheduled for surgery [5]. We divided urological procedures in three groups: the first is composed by emergent and urgent procedures that should be performed within few hours or the same day of diagnosis (Testicular torsion, Acute renal function impairment, Traumas, PUV, Paraphimosis, Priapism). The second is composed by scheduled procedures no longer deferrable that should be managed within few days/some weeks (Neoplasms, Non-symptomatic ureteral obstruction); finally, the third group includes all the procedures deferrable until the end of COVID-19 emergency (Congenital abnormalities, Hernias, Phimosis, Hydrocele, Non-obstructive lithiasis). The priorities following the peak of infections will follow the usual treatment schedule, considering the risk classes highlighted for urological pediatric patients, while maintaining a state of alert. Moreover, during the emergency period the optimal surgical timepoint will be passed over for some diseases (hypospadias, cryptorchidism) with possible risk for suboptimal outcome or increased social embarrassment and should be prioritized in the waiting list after going through the peak of infections [2]. Furthermore, ordinary radiology service is stopped; intervention as nephrostomy placement should be adopted only for emergency and minimized also for possible domiciliary management problems. Moreover, we reorganized access to the hospital: patients scheduled to undergo urgent or not deferrable planned surgery must be assessed for COVID-19; patients can be accompanied by only one parent; body temperature is measured with a thermal scanner before entering and a nasopharyngeal swab for SARS-Cov-2 is performed in a dedicated ward. If the test is negative, the children can be admitted to surgery. In case of an emergency procedure or if the swab results positive, the surgery is performed in a dedicated theatre and following the COVID-19 pathway specifically created. So far, only 8 out of 150 scheduled surgical patients (emergent/urgent, not scheduled patients are out of this count), who attended the hospital for intervention, resulted positive for COVID-19 swab and their interventions delayed as not urgent. Finally, the Royal College of Surgeons suggests to prefer open strategy to the risks of laparoscopic in aerosol diffusion of the virus [6]. In conclusion, pediatric population seem to be quite safe, but children could be the perfect silent vectors of this disease: avoid unnecessary procedures and reassess priorities is mandatory in a pandemic scenario.

Funding

None.

Conflicts of interest

None.
  5 in total

1.  Urology practice during the COVID-19 pandemic.

Authors:  Vincenzo Ficarra; Giacomo Novara; Alberto Abrate; Riccardo Bartoletti; Alessandro Crestani; Cosimo De Nunzio; Gianluca Giannarini; Andrea Gregori; Giovanni Liguori; Vincenzo Mirone; Nicola Pavan; Roberto M Scarpa; Alchiede Simonato; Carlo Trombetta; Andrea Tubaro; Francesco Porpiglia
Journal:  Minerva Urol Nefrol       Date:  2020-03-23       Impact factor: 3.720

2.  SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics.

Authors:  Qing Cao; Yi-Ching Chen; Chyi-Liang Chen; Cheng-Hsun Chiu
Journal:  J Formos Med Assoc       Date:  2020-03-02       Impact factor: 3.282

3.  Clinical and surgical consequences of the COVID-19 pandemic for patients with pediatric urological problems: Statement of the EAU guidelines panel for paediatric urology, March 30 2020.

Authors:  Josine S L T Quaedackers; Raimund Stein; Nikita Bhatt; Hasan Serkan Dogan; Lisette Hoen; Rien J M Nijman; Christian Radmayr; Mesrur Selcuk Silay; Serdar Tekgul; Guy Bogaert
Journal:  J Pediatr Urol       Date:  2020-04-09       Impact factor: 1.830

4.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

Review 5.  Coronavirus disease (COVID-19) and neonate: What neonatologist need to know.

Authors:  Qi Lu; Yuan Shi
Journal:  J Med Virol       Date:  2020-03-12       Impact factor: 20.693

  5 in total
  7 in total

Review 1.  The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.

Authors:  Gianmarco Lugli; Matteo Maria Ottaviani; Annarita Botta; Guido Ascione; Alessandro Bruschi; Federico Cagnazzo; Lorenzo Zammarchi; Paola Romagnani; Tommaso Portaluri
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

Review 2.  Scoping review: hotspots for COVID-19 urological research: what is being published and from where?

Authors:  Liang G Qu; Marlon Perera; Nathan Lawrentschuk; Rainy Umbas; Laurence Klotz
Journal:  World J Urol       Date:  2020-09-09       Impact factor: 4.226

3.  How the First Year of COVID-19 Affected Elective Pediatric Urology Patients: A Longitudinal Study Based on Waiting Lists and Surveys From 10 European Centers.

Authors:  Nikolai Juul; Aurélie Cazals; Aybike Hofmann; Virginia Amesty; Gilvydas Verkauskas; Barbara Dobrowolska-Glazar; Gundela Holmdahl; Maria Escolino; Jacques Birraux; Tamas Kovacs; Nicolas Kalfa; Magdalena Fossum
Journal:  Front Public Health       Date:  2022-04-28

4.  Impact of the COVID-19 pandemic on the surgical activity of Pediatric Urology: analysis of postoperative complications according to the Clavien-Dindo classification.

Authors:  L Merino-Mateo; C Tordable Ojeda; D Cabezalí Barbancho; A Gómez Fraile
Journal:  Actas Urol Esp (Engl Ed)       Date:  2020-09-17

5.  Changes in children's surgical services during the COVID-19 pandemic at a tertiary-level government hospital in a lower middle-income country.

Authors:  Md Abdullah Al Farooq; S M Humayun Kabir; Tanvir Kabir Chowdhury; Ayesha Sadia; Md Afruzul Alam; Tanzil Farhad
Journal:  BMJ Paediatr Open       Date:  2021-03-31

6.  Digital Approaches to Remote Pediatric Health Care Delivery During the COVID-19 Pandemic: Existing Evidence and a Call for Further Research.

Authors:  Sherif M Badawy; Ana Radovic
Journal:  JMIR Pediatr Parent       Date:  2020-06-25

7.  Genetic counseling during COVID-19 pandemic: Tuscany experience.

Authors:  Angelica Pagliazzi; Giorgia Mancano; Giulia Forzano; Fabiana di Giovanni; Giulia Gori; Giovanna Traficante; Achille Iolascon; Sabrina Giglio
Journal:  Mol Genet Genomic Med       Date:  2020-08-03       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.